secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K/A
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001213900-22-027102
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake AG reports Q1 2022 net loss of $15.9M; business combination with Helix closes raising $134.7M
--------------------------------------------------------------------------------

- Net loss of $15.88M for three months ended March 31, 2022; accumulated deficit of $69.5M.
- Cash of $8.8M; current liabilities exceeded current assets by $25.3M as of March 31, 2022.
- Short-term loans of $30M from BVF and Cormorant repaid after Business Combination closed April 5, 2022.
- Business Combination with Helix closed on April 5, 2022, raising $134.7M net of expenses.
- Company is a clinical-stage biopharma focused on Nanobody sonelokimab (SLK) for inflammatory diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390022027102/0001213900-22-027102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390022027102/ea159897-8ka1_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-027102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer